Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 134756, 11 pages
http://dx.doi.org/10.1155/2015/134756
Research Article

Results from the Registry of Atrial Fibrillation (AFABE): Gap between Undiagnosed and Registered Atrial Fibrillation in Adults—Ineffectiveness of Oral Anticoagulation Treatment with VKA

1EAP Tortosa 1-Oest, Institut Català Salut, SAP Terres de l’Ebre, Health Department, Generalitat de Catalunya, CAP Roquetes, 43520 Tortosa, Spain
2EAP Tortosa 1-Est, Institut Català Salut, SAP Terres de l’Ebre, Health Department, Generalitat de Catalunya, CAP Temple, 43500 Tortosa, Spain
3Miguel Hernández University, 03202 Elche, Spain
4EAP-Camarles-Aldea-Ampolla, Institut Català Salut, SAP Terres de l’Ebre, Health Department, Generalitat de Catalunya, CAP Ampolla, 43895 Tortosa, Spain
5EAP Tortosa-2-Oest, Institut Català Salut, SAP Terres de l’Ebre, Health Department, Generalitat de Catalunya, CAP Xerta, 43592 Tortosa, Spain
6Molecular Biology and Research Section, Hospital de Tortosa Verge de la Cinta, IISPV, IDIAP, 43500 Tortosa, Spain
7EAP Deltebre, Institut Català Salut, SAP Terres de l’Ebre, Health Department, Generalitat de Catalunya, CAP Deltebre, 43580 Tortosa, Spain
8Department of Cardiology, Hospital de Tortosa Verge de la Cinta, IISPV, 43500 Tortosa, Spain
9Department of Systems Management, Hospital de Tortosa Verge de la Cinta, Institut Català de la Salut, 43500 Tortosa, Spain
10Pla Director de la Malaltia Vascular Cerebral de Catalunya, Department Salut de la Generalitat de Catalunya, 08005 Barcelona, Spain

Received 26 November 2014; Revised 19 February 2015; Accepted 9 March 2015

Academic Editor: Anamika Bhargava

Copyright © 2015 Anna Panisello-Tafalla et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, A. J. Camm et al., “Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC),” European Heart Journal, vol. 31, no. 19, pp. 2369–2429, 2010. View at Publisher · View at Google Scholar
  2. J. Heeringa, D. A. M. van der Kuip, A. Hofman et al., “Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study,” European Heart Journal, vol. 27, no. 8, pp. 949–953, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Stefansdottir, T. Aspelund, V. Gudnason, and D. O. Arnar, “Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections,” Europace, vol. 13, no. 8, pp. 1110–1117, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Harmsen, L. Wilhelmsen, and A. Jacobsson, “Stroke incidence and mortality rates 1987 to 2006 related to secular trends of cardiovascular risk factors in Gothenburg, Sweden,” Stroke, vol. 40, no. 8, pp. 2691–2697, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. W. P. Wodchis, R. S. Bhatia, K. Leblanc, N. Meshkat, and D. Morra, “A review of the cost of atrial fibrillation,” Value in Health, vol. 15, no. 2, pp. 240–248, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Miyasaka, M. E. Barnes, B. J. Gersh et al., “Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence,” Circulation, vol. 114, no. 2, pp. 119–125, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. G. V. Naccarelli, H. Varker, J. Lin, and K. L. Schulman, “Increasing prevalence of atrial fibrillation and flutter in the United States,” The American Journal of Cardiology, vol. 104, no. 11, pp. 1534–1539, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. J. L. Clua-Espuny, R. Bosch-Princep, A. Roso-Llorach et al., “Diagnosed, undiagnosed and overall atrial fibrillation research on population over 60 year-old. AFABE study,” Cardiovascular System, vol. 2, no. 2, 2014. View at Publisher · View at Google Scholar
  9. A. Samol, M. Masin, R. Gellner et al., “Prevalence of unknown atrial fibrillation in patients with risk factors,” Europace, vol. 15, no. 5, pp. 657–662, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Oldgren, J. S. Healey, M. Ezekowitz et al., “Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY atrial fibrillation registry,” Circulation, vol. 129, no. 15, pp. 1568–1576, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. J. P. Casciano, Z. J. Dotiwala, B. C. Martin, and W. J. Kwong, “The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective,” Journal of Managed Care Pharmacy, vol. 19, no. 4, pp. 302–316, 2013. View at Google Scholar · View at Scopus
  12. C. L. Morgan, P. McEwan, A. Tukiendorf, P. A. Robinson, A. Clemens, and J. M. Plumb, “Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control,” Thrombosis Research, vol. 124, no. 1, pp. 37–41, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. J. L. Clua-Espuny, I. Lechuga-Duran, R. Bosch-Princep et al., “Prevalencia de la fibrilación auricular desconocida y la no tratada con anticoagulantes. Estudio AFABE,” Revista Española de Cardiología, vol. 66, no. 7, pp. 545–552, 2013. View at Publisher · View at Google Scholar
  14. B. F. Gage, A. D. Waterman, W. Shannon, M. Boechler, M. W. Rich, and M. J. Radford, “Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation,” The Journal of the American Medical Association, vol. 285, no. 22, pp. 2864–2870, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Pamukcu, G. Y. H. Lip, and D. A. Lane, “Simplifying stroke risk stratification in atrial fibrillation patients: Implications of the CHA2DS2-VASc risk stratification scores,” Age and Ageing, vol. 39, no. 5, pp. 533–535, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Pisters, D. A. Lane, R. Nieuwlaat, C. B. de vos, H. J. G. M. Crijns, and G. Y. H. Lip, “A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey,” Chest, vol. 138, no. 5, pp. 1093–1100, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Y. H. Lip, “Implications of the CHA2DS2-VASc and HAS-BLED scores for thromboprophylaxis in atrial fibrillation,” The American Journal of Medicine, vol. 124, no. 2, pp. 111–114, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. J. B. Olesen, G. Y. Lip, M. L. Hansen et al., “Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study,” British Medical Journal, vol. 342, article d124, 2011. View at Publisher · View at Google Scholar
  19. L. Friberg, M. Rosenqvist, and G. Y. H. Lip, “Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study,” European Heart Journal, vol. 33, no. 12, pp. 1500–1510, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Schmitt, J. Speckman, and J. Ansell, “Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range,” Journal of Thrombosis and Thrombolysis, vol. 15, no. 3, pp. 213–216, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Apostolakis, R. M. Sullivan, B. Olshansky, and G. Y. H. Lip, “Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score,” Chest, vol. 144, no. 5, pp. 1555–1563, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. D. A. Fitzmaurice, “Routine screening for detection of atrial fibrillation?” Future Cardiology, vol. 5, no. 3, pp. 213–214, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. D. A. Fitzmaurice, F. D. R. Hobbs, S. Jowett et al., “Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial,” British Medical Journal, vol. 335, no. 7616, pp. 383–386, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. M. S. Labrador García, R. Merino Segovia, C. Jiménez Domínguez, Y. García Salvador, A. Segura Fragoso, and C. Hernández Lanchas, “Prevalence of auricular fibrillation in people over 65 years of age in a health area,” Atencion Primaria, vol. 28, no. 10, pp. 648–651, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Morillas, V. Pallarés, J. L. Llisterri et al., “Prevalence of atrial fibrillation and use of antithrombotics in hypertensive patients aged ≥65 years. The FAPRES trial,” Revista Española de Cardiología (English Edition), vol. 63, no. 8, pp. 943–950, 2010. View at Publisher · View at Google Scholar
  26. L. Cea-Calvo, J. Redón, J. V. Lozano et al., “Prevalence of atrial fibrillation in the Spanish population aged 60 years or more. The PREV-ICTUS study,” Revista Espanola de Cardiologia, vol. 60, no. 6, pp. 616–624, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. J. L. Clua-Espuny, “Atrial fibrillation and cardiovascular comorbidities, survival and mortality: a real-life observational study,” Cardiology Research, vol. 5, no. 1, pp. 12–22, 2014. View at Publisher · View at Google Scholar
  28. A. Majeed, K. Moser, and K. Carroll, “Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994–1998: analysis of data from the general practice research database,” Heart, vol. 86, no. 3, pp. 284–288, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. P. D. Sobocinski, E. A. Rooth, V. F. Kull, M. von Arbin, H. Wallen, and M. Rosenqvist, “Improved screening for silent atrial fibrillation after ischaemic stroke,” Europace, vol. 14, no. 8, pp. 1112–1116, 2012. View at Publisher · View at Google Scholar
  30. C. Cowan, R. Healicon, I. Robson et al., “The use of anticoagulants in the management of atrial fibrillation among general practices in England,” Heart, vol. 99, pp. 1166–1172, 2013. View at Publisher · View at Google Scholar
  31. G. S. Yiin, D. P. Howard, N. L. Paul et al., “Age-specific incidence, outcome, cost, and projected future burden of atrial fibrillation-related embolic vascular events: a population-based study,” Circulation, vol. 130, no. 15, pp. 1236–1244, 2014. View at Publisher · View at Google Scholar
  32. M. P. Rao, S. D. Pokorney, and C. B. Granger, “Atrial fibrillation: a review of recent studies with a focus on those from the Duke Clinical Research Institute,” Scientifica, vol. 2014, Article ID 901586, 11 pages, 2014. View at Publisher · View at Google Scholar
  33. I. M. Ogilvie, N. Newton, S. A. Welner, W. Cowell, and G. Y. H. Lip, “Underuse of oral anticoagulants in atrial fibrillation: a systematic review,” The American Journal of Medicine, vol. 123, no. 7, pp. 638.e4–645.e4, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Cohen, D. Almoznino-Sarafian, I. Alon et al., “Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission,” Stroke, vol. 31, no. 6, pp. 1217–1222, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Giménez-García, J. L. Clua-Espuny, R. Bosch-Príncep et al., “El circuito asistencial de la fibrilación auricular en pacientes ambulatorios: estudio observacional Audit fibrilación auricular en el Baix Ebre,” Atención Primaria, vol. 46, no. 2, pp. 58–67, 2014. View at Publisher · View at Google Scholar
  36. D. E. Singer, A. S. Hellkamp, J. P. Piccini et al., “Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial,” The Journal of the American Heart Association, vol. 2, no. 1, Article ID e000067, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Wilke, A. Groth, S. Mueller et al., “Oral anticoagulation use by patients with atrial fibrillation in Germany: adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients,” Thrombosis and Haemostasis, vol. 107, no. 6, pp. 1053–1065, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Banerjee, N. Clementy, K. Haguenoer, L. Fauchier, and G. Y. Lip, “Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation Project,” The American Journal of Medicine, vol. 127, no. 10, pp. 972–978, 2014. View at Publisher · View at Google Scholar
  39. P. Bahrmann, M. Wehling, D. Ropers, J. Flohr, A. Leischker, and J. Röther, “Optimal stroke prevention in the geriatric patient with atrial fibrillation: position paper of an interdisciplinary expert panel,” Drug Research, 2014. View at Publisher · View at Google Scholar
  40. M. B. Sellers and L. K. Newby, “Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients,” American Heart Journal, vol. 161, no. 2, pp. 241–246, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. S. D. Fihn, C. M. Callahan, D. C. Martin, M. B. McDonell, J. G. Henikoff, and R. H. White, “The risk for and severity of bleeding complications in elderly patients treated with warfarin,” Annals of Internal Medicine, vol. 124, no. 11, pp. 970–979, 1996. View at Publisher · View at Google Scholar · View at Scopus
  42. J. L. Clua-Espuny, J. L. Piñol-Moreso, A. Panisello-Tafalla et al., “La atención sanitaria del ictus en el área Terres de l'Ebre desde la implantación del Código Ictus. Estudio Ebrictus,” Medicina Clínica, vol. 138, no. 14, pp. 138–344, 2012. View at Publisher · View at Google Scholar
  43. M. Marcucci, G. Y. Lip, R. Nieuwlaat, R. Pisters, H. J. Crijns, and A. Iorio, “roke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey,” The American Journal of Medicine, vol. 127, no. 10, pp. 979.e2–986.e2, 2014. View at Publisher · View at Google Scholar
  44. K. I. Gallacher, G. Batty, G. McLean et al., “Stroke, multimorbidity and polypharmacy in a nationally representative sample of 1,424,378 patients in Scotland: implications for treatment burden,” BMC Medicine, vol. 12, article 151, 2014. View at Publisher · View at Google Scholar
  45. J. Ansell, J. Hollowell, V. Pengo, F. Martinez-Brotons, J. Caro, and L. Drouet, “Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the International Study of Anticoagulation Management (ISAM),” Journal of Thrombosis and Thrombolysis, vol. 23, no. 2, pp. 83–91, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Løkkegaard, T. H. Pedersen, B. Lind, V. Siersma, and F. B. Waldorff, “Good quality of oral anticoagulation treatment in general practice using international normalised ratio point of care testing,” Danish Medical Journal, vol. 62, no. 2, Article ID A5010, 2015. View at Google Scholar
  47. F. Dentali, N. Riva, M. Crowther, A. G. G. Turpie, G. Y. H. Lip, and W. Ageno, “Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature,” Circulation, vol. 126, no. 20, pp. 2381–2391, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. J. R. González-Juanatey, J. Álvarez-Sabin, J. M. Lobos et al., “Análisis coste-efectividad de dabigatrán para la prevención de ictus y embolia sistémica en fibrilación auricular no valvular en España,” Revista Española de Cardiología, vol. 65, no. 10, pp. 901–910, 2012. View at Publisher · View at Google Scholar
  49. A. Janzic and M. Kos, “Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control,” PharmacoEconomics, 2014. View at Publisher · View at Google Scholar
  50. M. Wieloch, A. Sjlander, V. Frykman, M. Rosenqvist, N. Eriksson, and P. J. Svensson, “Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA,” European Heart Journal, vol. 32, no. 18, pp. 2282–2289, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. C. T. Ruff, R. P. Giugliano, E. Braunwald et al., “Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials,” The Lancet, vol. 383, no. 9921, pp. 955–962, 2014. View at Publisher · View at Google Scholar